Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
Mercaptopurine monohydrate
IMED Healthcare Ltd.
L01BB02
Mercaptopurine monohydrate
50 milligram(s)
Tablet
mercaptopurine
2019-11-01
PACKAGE LEAFLET: INFORMATION FOR THE USER PURI-NETHOL ® 50 MG TABLETS mercaptopurine monohydrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again − If you have any further questions, ask your doctor, pharmacist or nurse − This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours − If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET 1. What Puri-Nethol is and what it is used for 2. What you need to know before you take Puri-Nethol 3. How to take Puri-Nethol 4. Possible side effects 5. How to store Puri-Nethol 6. Contents of the pack and other information 1. WHAT PURI-NETHOL IS AND WHAT IT IS USED FOR Puri-Nethol contains the active substance mercaptopurine monohydrate. Mercaptopurine monohydrate belongs to a group of medicines called cytotoxics (also called chemotherapy) and works by reducing the number of new blood cells your body makes. Puri-Nethol is used to treat cancer of the blood (leukaemia) in adults, adolescents and children. This is a fast-growing disease which increases the number of new white blood cells. These new white blood cells are immature (not fully formed) and unable to grow and work properly. They therefore cannot fight infections and may cause bleeding. Ask your doctor if you would like more explanation about this disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PURI-NETHOL DO NOT TAKE PURI-NETHOL: If you are allergic to Puri-Nethol (mercaptopurine monohydrate) or any of the other ingredients of this medicine (see section 6). Do not get vaccinated with yellow fever vaccine whilst you are taking Puri-Nethol because it may be fatal. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist or nurse before taking Puri-Nethol if: • you have been vac Lire le document complet
Health Products Regulatory Authority 12 April 2022 CRN00CWLT Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Puri-Nethol 50 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg mercaptopurine monohydrate Excipient with known effect: lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet _Product imported from The Netherlands: _ Pale yellow, round tablets, biconvex, scored on one side, engraved PT and 50 on either side of the scoreline and plain on the other side. The scoreline is only to facilitate breaking of the tablets for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS As per PA1691/009/001 5 PHARMACOLOGICAL PROPERTIES As per PA1691/009/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Lactose monohydrate Maize starch Hydrolysed maize starch Stearic acid Magnesium stearate 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date for this product shall be the date shown on the bottle and outer package of the product on the market in the country of origin. Health Products Regulatory Authority 12 April 2022 CRN00CWLT Page 2 of 2 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 25 °C. Store in the original bottle and carton in order to protect from light. Keep the bottle tightly closed in order to protect from moisture. 6.5 NATURE AND CONTENTS OF CONTAINER Amber glass bottle with cap containing 25 tablets. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING SAFE HANDLING It is recommended that mercaptopurine monohydrate tablets should be handled following the prevailing local recommendations and/or regulations for the handling and disposal of cytotoxic agents. DISPOSAL Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER IMED Healthcare Ltd. Unit 625 Kilshane Avenue Northwest Business Park Ballycoolin Dublin 15 Ireland 8 PARALLEL PRODUCT AUTHORISATIO Lire le document complet